01 Advancements in At-Home HPV Self-Sampling TechnologiesThe cervical cancer screening market is witnessing a shift toward self-sampling technologies as healthcare systems introduce alternative methods for collecting samples for human papillomavirus (HPV) testing. This transition encourages the use of validated HPV DNA testing methods and self-collection kits within cervical screening programs. The WHO recommends HPV DNA testing as the preferred primary screening method and recognizes self-sampling as an additional approach to cervical screening, reflecting changes in sample collection practices.
02 Integration of Artificial Intelligence in Cervical Cell AnalysisThe influence of artificial intelligence (AI) is changing how cervical screening laboratories analyze cell samples and identify abnormalities. This transition is encouraging the integration of deep-learning algorithms with digital pathology workflows to support more consistent analysis and reduce slide interpretation time.
01 Supply chain disruptions are expected to have a moderate impact on the cervical cancer screening market share due to dependence on diagnostic kits, laboratory reagents, sample collection devices, and transportation networks. The market is likely to follow an S-shaped recovery, with gradual restoration of diagnostic material supplies and laboratory operations. Supply chain constraints could reduce market growth by approximately 1.0–1.5 percentage points, lowering the projected CAGR of 11.49% to around 9.99%–10.49%. As supply conditions normalize, the cervical cancer screening market is expected to return to 11.49%.
01 The cervical cancer screening market forecasts strategic investment activity driven by the development of at-home screening solutions, advancements in HPV testing technologies, expansion of self-collection methods, and efforts to improve access to early cancer detection. In January 2025, Teal Health raised USD 10 million in a seed extension round led by Emerson Collective and Forerunner, bringing its total funding at that time to USD 23 million.
01 High Screening Costs and Inadequate Healthcare Infrastructure Restrain Market ExpansionCervical cancer screening involves expenses related to HPV testing, clinical consultations, sample collection, and follow-up diagnostic procedures. These costs limit affordability for women in low-income populations, particularly in regions with limited insurance coverage or publicly funded screening services. Consequently, eligible women may delay or skip routine screening, reducing the adoption of cervical cancer screening services.Inadequate healthcare infrastructure and shortages of trained healthcare professionals limit the availability of cervical cancer screening services in rural and underserved regions. Limited access to diagnostic laboratories, screening facilities, and follow-up care creates delays in testing and diagnosis.
01 Expansion of Public-Private Screening Partnerships and Integration into Primary Healthcare Offers Growth Opportunities to Market PlayersCollaboration between government health programs, private healthcare providers, diagnostic laboratories, and non-governmental organizations creates opportunities to expand cervical cancer screening coverage. These partnerships improve access to affordable screening services, strengthen referral networks, and reach underserved populations. Healthcare providers and diagnostic companies can benefit from increased testing volumes as screening programs expand across community and primary healthcare facilities.Integration of cancer screening into routine primary healthcare and existing women’s health programs creates additional opportunities to improve service accessibility. The World Health Organization recommends scaling up HPV-based screening alongside vaccination and treatment services, encouraging healthcare systems to strengthen coordinated prevention programs.
August 2026 India’s Technology Development Board entered into an agreement with Griva Healthcare Pvt. Ltd. to support the manufacturing and commercialization of GrivaVision, an indigenous portable digital colposcope with AI-assisted capabilities for detecting precancerous cervical lesions.
May 2026 TruScreen Group appointed Albatros Health Care LLC as its distributor in Uzbekistan and initiated preparations for a pilot clinical study involving approximately 600 participants in Tashkent.
February 2026 Hologic received U.S. FDA approval for its Aptima HPV Assay as a primary cervical cancer screening option using clinician-collected samples.